A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: Effects on compliance and quality of life

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 109, Issue 8, 2002, Pages 874-885

  Voss, Simon ^a   Quail, Deborah ^a   Dawson, Alison ^a   Bäckström, Tjorbörn ^b   Aguas, Fernanda ^c   Erenus, Mithat ^d   The, Hok Sien ^e   Bonnar, John ^f   De Geyter, Christian ^g   Hunter, Myra ^h   Nickelsen, Thomas ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c Maternidade Bissaya Barreto ^*  (Portugal)

^d MARMARA UNIVERSITY   (Turkey)

^e ST ANTONIUS HOSPITAL   (Netherlands)

^f ST JAMES S HOSPITAL   (Ireland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; NORETHISTERONE ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; EDEMA; EUROPE; FEMALE; HEADACHE; HEALTH CARE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INFLUENZA; ISRAEL; LEG CRAMP; MAJOR CLINICAL STUDY; MASTALGIA; MEDICAL PRACTICE; MENTAL INSTABILITY; MOOD DISORDER; MULTICENTER STUDY; NORMAL HUMAN; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOUTH AFRICA; STATISTICAL SIGNIFICANCE; THROMBOPHLEBITIS; TREATMENT WITHDRAWAL; UTERINE CERVIX DISEASE; UTERUS; VAGINA BLEEDING; VAGINITIS; VASODILATATION; VISUAL ANALOG SCALE; WEIGHT GAIN; BREAST DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; PAIN; TREATMENT REFUSAL;

AGED; BREAST DISEASES; DOUBLE-BLIND METHOD; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PAIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT REFUSAL; VASODILATION;

EID: 0242349226     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2002.01510.x     Document Type: Article

References (37)

1. Peck C.L., King N.J. Compliance and the doctor-patient relationship. Drugs. 30:1985;78-84.
2. Berman R.S., Epstein R.S., Lydick E.G. Compliance of women in taking estrogen replacement therapy. J Women's Health. 5:1996;213-220.
3. Faulkner D.L., Young C., Hutchins D., Schwed McCollam J. Patient noncompliance with hormone replacement therapy: a nationwide estimate using large prescription claims database. Menopause. 5:1998;226-229.
4. Castelo-Branco C., Figueras F., Sanjuan Aet al. Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause. 6:1999;307-311.
5. Luciano A.A., de Souza M.J., Schoenfeld M.J., Nulsen J.C., Halvorsen C.V. Evaluation of low-dose estrogen and progestin therapy in postmenopausal women. J Reprod Med. 38:1993;207-214.
6. Byrjalsen I., Thormann L., Meinecke B., Riis B.J., Christiansen C. Sequential estrogen and progesterone therapy: assessment of progestational effects on the postmenopausal endometrium. Obstet Gynecol. 79:1992;524-528.
7. Pirhonen J.P., Vuenuto M.H., Makinen J.I., Salmi T.A. Long-term effects of hormone replacement therapy on the uterus and on uterine circulation. Am J Obstet Gynecol. 168:1992;620-623.
8. Grady D., Rubin S.M., Petitti DBet al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
9. Colditz G.A., Hankinson S.E., Hunter DJet al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332:1995;1589-1593.
10. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 without breast cancer. Lancet. 350:1997;1047-1059.
11. Beresford S.A.A., Weiss N.S., Voigt L.F., McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 349:1997;458-461.
12. Jones C.D., Jevnikar M.G., Pike AJet al. Antiestrogens: 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b] thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem. 27:1984;1057-1066.
13. Draper M.W., Flowers D.E., Neild J.A., Huster W.J., Zerbe R.L. Antiestrogenic properties of raloxifene. Pharmacology. 50:1995;209-217.
14. Delmas P., Bjarnason N., Mitlak Bet al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 337:1997;1641-1647.
15. Ettinger B., Black D., Mitlak Bet al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 282:1999;637-644.
16. Walsh B.W., Kuller L.H., Wild RAet al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 279:1998;1445-1451.
17. Kauffman R.F., Bean J.S., Fahey K.J., Cullinan G.J., Cox D.A., Bensch W.R. Raloxifene and estrogen inhibit intimal thickening in response to balloon injury in carotid arteries of male and ovariectomized female rats. J Cardiovasc Pharmacol. 36:2000;459-465.
18. Figtree G.A., Lu Y.Q., Webb C.M., Collins P. Raloxifene acutely relaxes coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation. 100:2000;1095-1101.
19. Bjarnason N.H., Haarbo J., Byrjalsen I., Kauffman R.F., Knadler M.P., Christiansen C. Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits. Clin Endocrinol. 52:2000;225-233.
20. Zoma W.D., Baker R.S., Clark K.E. Coronary and uterine responses to raloxifene in the sheep. Am J Obstet Gynecol. 182:2000;521-528.
21. Zuckerman S.H., Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY 139481 HCl). Atherosclerosis. 126:1996;65-75.
22. Clarkson T.B., Anthony M.S., Jerome C.P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab. 83:1998;721-726.
23. Barrett-Connor E., Grady D., Sashegyi Aet al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 287(7):2002;847-857.
24. Boss S.M., Huster W.J., Neild J.A., Glant M., Eisenhut C.C., Draper M.W. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 177:1997;1458-1464.
25. Cummings S.R., Eckert S., Krueger KAet al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA. 281:1999;2189-2197.
26. Davies G.C., Huster W.J., Lu Y., Plouffe L. Jr., Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 93(4):1999;558-565.
27. Davies G.C., Huster W.J., Shen Wet al. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause. 6:1999;188-195.
28. Eli Lilly and Company. Evista Summary of Product Characteristics. March 2000.
29. Hulley S., Grady D., Bush Tet al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
30. Hunter M. The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health. 7:1992;45-54.
31. Wren B.G., Brown L. Compliance with hormonal replacement therapy. Maturitas. 13:1991;17-21.
32. Ettinger B., Pressman A., Bradley C. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen. Menopause. 5(3):1998;152-156.
33. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., Cummings S.R. Estrogen replacement therapy and fractures in older women. Study of Osteoporosis Fracture Research Group. Ann Intern Med. 122:1995;9-16.
34. Vihtamäki T., Savilahti R., Tuimala R. Why do postmenopausal women discontinue hormone replacement therapy? Maturitas. 33:1999;99-105.
35. Melnikow J., Kiefe C. Patient compliance and medical research. J Gen Intern Med. 9:1994;96-105.
36. Björn I., Bäckström T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas. 32:1999;77-86.
37. Ettinger B., Pressman A., Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause. 6:1999;282-289.